HRMY Stock Overview
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Harmony Biosciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.82 |
| 52 Week High | US$39.27 |
| 52 Week Low | US$18.61 |
| Beta | 0.72 |
| 11 Month Change | 9.04% |
| 3 Month Change | 13.45% |
| 1 Year Change | -7.55% |
| 33 Year Change | 24.46% |
| 5 Year Change | n/a |
| Change since IPO | -11.32% |
Recent News & Updates
Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet
Jul 15
Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Jun 07Recent updates
Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet
Jul 15Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Jun 07Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 03These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely
Apr 04Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings
Feb 09Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Mar 21Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?
Dec 01Harmony Biosciences: In Harmony
Sep 23We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease
Aug 05Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M
Aug 02Harmony Biosciences: Steady Revenue Generator Looking For A Future
May 26Harmony Biosciences: Strong Growth At A Reasonable Price
Mar 04Our First Look At Harmony Biosciences
Nov 04Harmony Biosciences Holdings' (NASDAQ:HRMY) Promising Earnings May Rest On Soft Foundations
Aug 17Shareholder Returns
| HRMY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.8% | 0.004% | -2.4% |
| 1Y | -7.5% | 18.8% | 17.5% |
Return vs Industry: HRMY underperformed the US Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: HRMY underperformed the US Market which returned 19.8% over the past year.
Price Volatility
| HRMY volatility | |
|---|---|
| HRMY Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HRMY has not had significant price volatility in the past 3 months.
Volatility Over Time: HRMY's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 246 | Jeffrey Dayno | www.harmonybiosciences.com |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons.
Harmony Biosciences Holdings, Inc. Fundamentals Summary
| HRMY fundamental statistics | |
|---|---|
| Market cap | US$1.90b |
| Earnings (TTM) | US$137.70m |
| Revenue (TTM) | US$617.51m |
13.5x
P/E Ratio3.0x
P/S RatioIs HRMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HRMY income statement (TTM) | |
|---|---|
| Revenue | US$617.51m |
| Cost of Revenue | US$127.94m |
| Gross Profit | US$489.57m |
| Other Expenses | US$351.87m |
| Earnings | US$137.70m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 06, 2024
| Earnings per share (EPS) | 2.42 |
| Gross Margin | 79.28% |
| Net Profit Margin | 22.30% |
| Debt/Equity Ratio | 36.9% |
How did HRMY perform over the long term?
See historical performance and comparison